Rational computational design of fourth-generation egfr inhibitors to combat drug-resistant non-small cell lung cancer

Article abstract of DOI:10.3390/ijms21239323

Although the inhibitors of singly mutated epidermal growth factor receptor (EGFR) kinase are effective for the treatment of non-small cell lung cancer (NSCLC), their clinical efficacy has been limited due to the emergence of various double and triple EGFR mutants with drug resistance. It has thus become urgent to identify potent and selective inhibitors of triple mutant EGFRs resistant to first-, second-, and third-generation EGFR inhibitors. Herein, we report the discovery of potent and highly selective inhibitors of EGFR exon 19 p.E746_A750del/EGFR exon 20 p.T790M/EGFR exon 20 p.C797S (d746-750/T790M/C797S) mutant, which were derived via two-track virtual screening and de novo design. This two-track approach was performed so as to maximize and minimize the inhibitory activity against the triple mutant and the wild type, respectively. Extensive chemical modifications of the initial hit compounds led to the identification of several low-nanomolar inhibitors of the d746-750/T790M/C797S mutant. Among them, two compounds exhibited more than 10⁴-fold selectivity in the inhibition of EGFR^{d746-750/T790M/C797S} over the wild type. The formations of a hydrogen bond with the mutated residue Ser797 and the van der Waals contact with the mutated residue Met790 were found to be a common feature in the interactions between EGFR^{d746-750/T790M/C797S} and the fourth-generation inhibitors. Such an exceptionally high selectivity could also be attributed to the formation of the hydrophobic contact with a Gly loop residue or the hydrogen bond with Asp855 in the activation loop. The discovery of the potent and selective EGFR^{d746-750/T790M/C797S} inhibitors were actually made possible by virtue of the modified protein–ligand binding free energy function involving a new hydration free energy term with enhanced accuracy. The fourth-generation EGFR inhibitors found in this work are anticipated to serve as a new starting point for the discovery of anti-NSCLC medicines to overcome the problematic drug resistance.

Full text of DOI:10.3390/ijms21239323

International Journal of
Molecular Sciences
Article
Rational Computational Design of Fourth-Generation
EGFR Inhibitors to Combat Drug-Resistant
Non-Small Cell Lung Cancer
Hwangseo Park 1,*, Hoi-Yun Jung 2,3, Kewon Kim 2,3, Myojeong Kim 2,3 and
Sungwoo Hong 2,3,
*
1
Department of Bioscience and Biotechnology, Institute of Anticancer Medicine Development,
Sejong University, 209 Neungdong-ro, Kwangjin-gu, Seoul 05006, Korea
Center for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS), Daejeon 34141, Korea;
spurs9@kaist.ac.kr (H.-Y.J.); kkw105701@kaist.ac.kr (K.K.); mymyo24@kaist.ac.kr (M.K.)
Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST),
Daejeon 34141, Korea
2
3
*
Correspondence: hspark@sejong.ac.kr (H.P.); hongorg@kaist.ac.kr (S.H.); Tel.: +82-2-3408-3766 (H.P.);
+82-42-350-2811 (S.H.); Fax: +82-2-3408-4334 (H.P.); +82-42-350-2812 (S.H.)
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Received: 30 October 2020; Accepted: 4 December 2020; Published: 7 December 2020
Abstract: Although the inhibitors of singly mutated epidermal growth factor receptor (EGFR) kinase
are effective for the treatment of non-small cell lung cancer (NSCLC), their clinical efficacy has been
limited due to the emergence of various double and triple EGFR mutants with drug resistance. It has
thus become urgent to identify potent and selective inhibitors of triple mutant EGFRs resistant to
first-, second-, and third-generation EGFR inhibitors. Herein, we report the discovery of potent and
highly selective inhibitors of EGFR exon 19 p.E746_A750del/EGFR exon 20 p.T790M/EGFR exon
20 p.C797S (d746-750/T790M/C797S) mutant, which were derived via two-track virtual screening
and de novo design. This two-track approach was performed so as to maximize and minimize the
inhibitory activity against the triple mutant and the wild type, respectively. Extensive chemical
modifications of the initial hit compounds led to the identification of several low-nanomolar inhibitors
of the d746-750/T790M/C797S mutant. Among them, two compounds exhibited more than 104-fold
selectivity in the inhibition of EGFRd746-750/T790M/C797S over the wild type. The formations of a
hydrogen bond with the mutated residue Ser797 and the van der Waals contact with the mutated
residue Met790 were found to be a common feature in the interactions between EGFRd746-750/T790M/C797S
and the fourth-generation inhibitors. Such an exceptionally high selectivity could also be attributed to
the formation of the hydrophobic contact with a Gly loop residue or the hydrogen bond with Asp855
in the activation loop. The discovery of the potent and selective EGFRd746-750/T790M/C797S inhibitors
were actually made possible by virtue of the modified protein–ligand binding free energy function
involving a new hydration free energy term with enhanced accuracy. The fourth-generation EGFR
inhibitors found in this work are anticipated to serve as a new starting point for the discovery of
anti-NSCLC medicines to overcome the problematic drug resistance.
Keywords: virtual screening; de novo design; EGFR; fourth-generation inhibitor; drug resistance
1. Introduction
Epidermal growth factor receptor (EGFR) plays a key role in regulating various intracellular
signaling for tumor cell proliferation, differentiation, migration, and invasion [
of EGFR kinase is responsible for the pathogenesis and the progression of approximately 10–15% of lung
adenocarcinomas, which are the main subtype of non-small cell lung cancer (NSCLC) [ ]. The most
1,2]. Deregulated activity
3–5
Int. J. Mol. Sci. 2020, 21, 9323; doi:10.3390/ijms21239323
www.mdpi.com/journal/ijms

Int. J. Mol. Sci. 2020, 21, 9323
2 of 23
constitutively activating mutations include the L858R single point mutation and the deletion of
Glu746-Ala750 (d746-750) [ ]. In this regard, it has served as a good therapeutic treatment of NSCLC
6,7
to impair the kinase activity of the oncogenic mutants with first-generation EGFR inhibitors [8–11].
However, targeting the L858R and d746-750 mutants by the first-generation EGFR inhibitors
became problematic with the manifestation of drug resistance in NSCLC patients. This acquired
resistance was due to a secondary somatic mutation (T790M) in the hinge region [12–15], which caused
the increase in the steric repulsions with the first-generation inhibitor drugs. This triggered the
discovery of a number of the second-generation EGFR inhibitors to surmount the drug resistance [16].
Despite the alleviation of drug resistance, the clinical application of the second-generation EGFR
inhibitors was limited owing to the severe side effects caused by the simultaneous inhibition of the
mutant and the wild-type EGFR. Accordingly, a great deal of efforts has been devoted to the discovery
of the new EGFR inhibitors specific for the drug-resistant d746-750/T790M and L8585R/T790M double
mutants [17–19], which was characteristic of the third-generation inhibitors.
A common mechanistic feature of the second- and the third-generation EGFR inhibitors lies in
the irreversible inhibition of the mutant kinase activity through the formation of a covalent bond
with the nucleophilic side chain of Cys797. This is made possible because the inhibitors possess a
suitable electrophilic group susceptible to nucleophilic attack by the side-chain thiolate group of Cys797
at the lip of the ATP-binding site. However, a drug resistance problem was raised again with the
appearance of a tertiary mutation (C797S), which has the effect of preventing the covalent interactions
with residue 797 [20–23]. The identification of L858R/T790M/C797S and d746-750/T790M/C797S
mutant inhibitors has therefore been actively pursued to target the NSCLC cells resistant to the
second- and the third-generation EGFR inhibitors. Although most triple mutant inhibitors were
insufficient as a lead compound due to the higher biochemical potency against the wild type [24
some derivatives of 2-aryl-4-aminoquinazoline and 5-methylpyrimidopyridone proved to be good
candidates for anti-NSCLC agent with high selectivity in the inhibition of the triple mutant [27 28].
–26],
,
The triple mutant inhibitors to suppress the resistance induced by C797S mutation are termed the
fourth-generation EGFR inhibitors for which selectivity over the wild-type EGFR is also necessary to
circumvent the severe potential side effects [29]. In recent years, the discovery of the fourth-generation
inhibitors to specifically inhibit the triple EGFR mutants responsible for the resistance to second- and
third-generation inhibitor drugs has become the focus of anti-NSCLC drug development [30].
This work aimed at the discovery of the potent and specific inhibitors of the d746-750/T790M/C797S
mutant EGFR based on the two-track virtual screening, de novo design, chemical synthesis, and enzyme
inhibition assays. The two-track approach was adopted to find molecules with maximal and minimal
inhibitory activity against the triple mutant and the wild type, respectively. To augment the likelihood
of finding the new fourth-generation EGFR inhibitors in the early stage of discovery, the protein–ligand
binding free energy function to evaluate the putative inhibitors was modified by introducing an
adequate hydration energy function. This preliminary step is necessary because a poor correlation
between the computational and experimental results for protein–ligand binding affinity stems in a large
part from the underestimation of ligand hydration effects [31]. Through the binding mode analysis
with docking simulations, we also address the energetic and structural features associated with the
mechanism of action for the fourth-generation EGFR inhibitors.
2. Results and Discussion
2.1. Structure-Based Virtual Screening of the Fourth-Generation EGFR Inhibitors
Rational design of the fourth-generation EGFR inhibitors was a formidable task because of the
lack of 3D structure of the d746-750/T790M/C797S triple mutant. Accordingly, the virtual screening and
de novo design started with the preparation of a relevant structural model for the kinase domain of the
d746-750/T790M/C797S mutant by homology modeling. The atomic coordinates of the target protein
were produced using the active form of the L858R/T790M/C797S mutant as the structural template [28].

Int. J. Mol. Sci. 2020, 21, 9323
3 of 23
The optimized structural model for the d746-750/T790M/C797S mutant was validated with the ProSa
2003 program, which has been widely used as a valuable computational tool for examining whether the
interactions of each amino-acid residue with the rest part of the protein are maintained favorably [32].
This free energy profile for individual amino acids could be obtained with the knowledge-based mean
field potential.
Figure 1 shows the free energy profile of the homology-modeled kinase domain of the
d746-750/T790M/C797S mutant in comparison with that of the L858R/T790M/C797S mutant,
which served as the structural template. It is remarkable to see that the target protein exhibits
the better energy profile than the template in most parts of the protein especially in the central region
between the N- and C-terminal domains. Furthermore, the energy values remain negative throughout
the amino acid residues, implying that the homology-modeled structure of the d746-750/T790M/C797S
mutant would be physically acceptable. Based on the good energetic features, the structure of the kinase
domain of the d746-750/T790M/C797S mutant constructed with homology modeling was adopted
as the receptor model for the virtual screening and de novo design to find the fourth-generation
EGFR inhibitors.
Figure 1. Comparative view of the ProSa energy profile of the homology-modeled structure of
d746-750/T790M/C797S mutant and that of the template.
The applicability of virtual screening and de novo design has been limited owing to the inaccurate
nature of the scoring function for estimating the protein–ligand binding affinity [33,34]. In particular,
the binding free energy functions of popular docking programs tend to underestimate the ligand
dehydration effects in the protein–ligand association. This may inevitably culminate in overestimating
the biochemical potency of a molecule with many hydrophilic groups [31]. Prior to conducting the
virtual screening, therefore, we modified the dehydration term in the original scoring function within
the framework of the extended solvent-contact model to enhance the predictive capability.
Virtual screening began with the preparation of a chemical library from which the tight-binding
inhibitor scaffolds for the d746-750/T790M/C797S mutant could be found by docking simulations. This
docking library was constructed by collecting a total of approximately 370,000 ‘Rule-of-Five’-compliant
molecules [35] with molecular weights ranging from 300 and 400 atomic mass units (amu)
among the commercially available compounds. Virtual screening of the fourth-generation EGFR
inhibitors was then carried out through the docking simulations in the ATP-binding pockets of the
d746-750/T790M/C797S mutant and the wild type of EGFR. This two-track approach was intended

Int. J. Mol. Sci. 2020, 21, 9323
4 of 23
to collect the putative inhibitors with binding free energies lower than -10 kcal/mol and higher than
6.0 kcal/mol with respect to the triple mutant and the wild type, respectively, which corresponds to at
least 1000-fold difference in binding affinities. As a result that the bidentate hydrogen-bond interactions
in the hinge region were characteristic of the effective fourth-generation EGFR inhibitors [27 28],
−
,
only molecules capable of forming the two hydrogen bonds with backbone groups of residues 791-795
were selected with the distance criteria of <3.5 Å after all molecules in the docking library were screened.
Only 26 compounds satisfied all the filtration criteria as indicated in Figure 2. This small number
of virtual hits exemplifies the difficulty in discovering the fourth-generation inhibitors that are specific
for the triple mutant. This can be understood in the context of the high structural similarity between the
mutant and the wild type. All virtual hits were assessed for the presence of inhibitory activity against
the d746-750/T790M/C797S mutant and the wild type via in vitro radiometric ([γ
-33P]-ATP) kinase
assays (Reaction Biology Corp., Malvern, PA, USA). As a consequence of virtual and experimental
screening, four molecules were identified as low-micromolar inhibitors of d746-750/T790M/C797S
mutant. Actually, none of the four molecules have previously been reported as EGFR kinase inhibitors.
With respect to disproving the possibility of acting as a false positive in enzyme inhibition assays, all four
inhibitors were examined in the public ZINC database [36] to confirm the lack of any substructure in
pan assay interference compounds (PAINS) [37].
Figure 2. Flowchart for the discovery of the fourth-generation epidermal growth factor receptor (EGFR)
inhibitors specific for the d746-750/T790M/C797S mutant using the two-track virtual screening and
enzyme inhibition assays.

Int. J. Mol. Sci. 2020, 21, 9323
5 of 23
Chemical structures and biochemical potencies of the four inhibitors of d746-750/T790M/C797S
mutant EGFR are summarized in Figure 3 and Table 1, respectively. It is a common structural feature
for 1–4 to possess several polar groups and nonpolar aromatic rings, therefore, both hydrogen-bond
and van der Waals interactions are likely to serve as the major binding forces to accommodate them in
the ATP-binding site of the d746-750/T790M/C797S mutant.
Figure 3. Chemical structures of the four inhibitors of the d746-750/T790M/C797S mutant EGFR
identified from virtual and biochemical screening.
Table 1. IC50 values of the four inhibitors of the d746-750/T790M/C797S mutant EGFR in comparison
with those for the wild type. Selectivity index is also given by the ratio of IC50 for the wild type to that
for the triple mutant.
IC50 (µM)
Selectivity Index
Inhibitor
mutant
(IC50WT/IC50
)
Wild Type
d746-750/T790M/C797S
1
2
3
4
72.7 ± 4.8
37.1 ± 2.3
2.11 ± 0.56
1.73 ± 0.38
2.89 ± 0.91
0.802 ± 0.055
34.5
21.4
12.3
35.5 ± 3.5
0.00588 ± 0.00098
0.00733
Values are given by the mean ± standard deviations of two experiments.
As listed in Table 1, all four inhibitors exhibited good biochemical potency against the triple
mutant with IC50 values ranging from 0.8 to 3 M. Furthermore, compounds 1–3 appear to be selective
µ
in the inhibition of the triple mutant over the wild type by a factor of 10–35. They are therefore worthy of
further development with structural modifications to maximize the inhibitory activity against NSCLC
cells resistant to second- and third-generation EGFR inhibitor drugs.
molecular core for designing the new fourth-generation EGFR inhibitors due to the highest selectivity
and good inhibitory activity against the triple mutant. and contain 2-aryl-4-aminoquinazoline
1 seems to serve as an effective
2
3
and 1,3,5-triazin-2-amine moieties, respectively, which were also included in the previously identified
inhibitors of the triple mutant [27].
It is quite unexpected that
4 reveals 136-fold higher inhibitory activity against the wild type than
against the d746-750/T790M/C797S mutant, indicating that its binding affinity for the wild type was

Int. J. Mol. Sci. 2020, 21, 9323
6 of 23
underestimated to a great extent in the precedent virtual screening. Thus, the scoring function used in
this work remains imperfect despite the modification by substituting a sophisticated hydration energy
term. Although
4 was found accidentally as a potent inhibitor of the wild-type EGFR, it deserves
consideration for further development as a new first-generation inhibitor because the biochemical
potency reached the nanomolar level (Table 1) without any chemical modification.
To find the structural relevance for low-micromolar activity of the newly discovered EGFR
inhibitors, their binding modes were derived with docking simulations using the modified scoring
function. Overlaid in Figure 4 are the docked poses of 1–4 around the ATP-binding site of the
d746-750/T790M/C797S mutant. All four inhibitors appear to be accommodated in the well-established
binding pocket comprising the glycine-rich loop (Gly loop, residues 718–726), the hinge region (residues
791–795) of the ATP-binding site, and the residues at the interface of the N- (700–860) and C-terminal
(861–1014) domains. It is also a common complexation pattern that the inhibitors reside in close
proximity to the side chains of Met790 and Ser797, which were mutated from Thr790 and Cys797 of the
wild-type EGFR, respectively. The interactions with these mutated residues would be necessary for the
specific inhibition of the d746-750/T790M/C797S mutant. To find the potential allosteric sites that could
accommodate 1–4, additional docking simulations were carried out using 3D grid maps extended to
include the whole EGFR kinase domain. Nonetheless, no peripheral binding site was identified in
which 1–4 could be stabilized with a negative value of binding free energy. Therefore, compounds
1–4 are likely to impair the kinase activity of the d746-750/T790M/C797S mutant through the specific
binding in the ATP binding site.
Figure 4. Comparative view of the predicted binding conformations of 1-4 in the ATP-binding site of
d746-750/T790M/C797S mutant EGFR. The carbon atoms of the protein and 1–4 are colored in violet,
green, black, gray, and pink, respectively.
As a result that
1 and 2 are low-micromolar inhibitors of the d746-750/T790M/C797S mutant
with reasonably good selectivity over the wild type, their complexation patterns in the ATP-binding

Int. J. Mol. Sci. 2020, 21, 9323
7 of 23
site would provide great insight into how to promote the potency and selectivity through chemical
modifications. Figure 5 illustrates the most stable binding modes and obtained with docking
simulations using the modified scoring function. The carbonyl oxygen of receives a hydrogen bond
1
2
1
from the backbone amidic moiety of Met793 in the hinge region while the phenolic moiety donates a
hydrogen bond to the backbone aminocarbonyl oxygen of Leu718 in the Gly loop. These two hydrogen
bonds seem to play a key role in binding of
the middle of the ATP-binding pocket. The third hydrogen bond is observed between the terminal
piperidine moiety of and the sidechain hydroxyl group of Ser797, which augments the strength of
EGFRd746-750/T790M/C797S
binding. This interaction would also be important in terms of selectivity
because it involves the mutated sidechain at residue 797. looks stabilized further through the
1 to the mutant EGFR because they are established in
1
-
1
1
hydrophobic contacts with the nonpolar side chains of Leu718, Val726, Phe723, Met790, Leu792, and
Leu844. In particular, we note that three leucine residues (Leu718, Leu792, and Leu844) accommodate
the 6-hydroxybenzofuran-3-one moiety of
1 around the two hydrogen bonds in the ATP-binding
site. These interactions are assumed to contribute to the strengthening of the vicinal hydrogen bonds
by preventing the approach of solvent water molecules. Significant synergistic effects are therefore
anticipated in binding affinity by positioning the two hydrogen bonds in proximity to the hydrophobic
contacts. Indeed, it has served as a facile strategy in the optimization of biochemical potency to
reinforce the hydrogen bonds cooperatively with the hydrophobic interactions in complexation with
the target proteins [38,39].
Figure 5. Detailed interaction patterns of
mutant EGFR. Carbon atoms of and
1
2
and
2 in the ATP-binding site of the d746-750/T790M/C797S
1
are colored in green and black, respectively. Hydrogen
bond interactions are represented with dotted lines. The red dotted circle indicates a peripheral
binding pocket.
The binding mode of
that three hydrogen bonds are involved in the complexation. In particular, we note that one of the
nitrogens on the pyrimidine ring and the terminal phenolic moiety of receives and donates a hydrogen
2 1 in
in the ATP-binding site of EGFRd746-750/T790M/C797S is similar to that of
2
bond from the backbone amidic nitrogen of Met793 and to the aminocarbonyl oxygen of Gln791,
respectively. These bidentate hydrogen bonds are supported by the neighboring van der Waals contacts

Int. J. Mol. Sci. 2020, 21, 9323
8 of 23
between the inhibitor phenyl ring and the sidechain of the mutated Met790. This kind of interaction
pattern was actually observed in a variety of EGFR-inhibitor complexes, irrespective of the mutational
status of EGFR [40]. In the calculated structure of EGFRd746-750/T790M/C797S
-
2
complex, an additional
hydrogen bond is found at the bottom of the ATP-binding site between the –NH moiety attached to
the pyrimidine ring of and the side-chain hydroxyl group of the mutated Ser797. This hydrogen
2
bond seems to contribute to the selective inhibition of the triple mutant because the substitution of
serine for cysteine at residue 797 is the tertiary mutation to afford the resistance to the second- and
third-generation EGFR inhibitors. The stabilization of
due to the hydrophobic interactions with the nonpolar side chains of Leu718, Val726, Phe723, Met790,
Leu792, and Leu844. On the basis of the structural features in the calculated EGFRd746-750/T790M/C797S
complex, it is most likely that the low-micromolar inhibitory activity of would stem from the multiple
hydrogen bonds facilitated by the hydrophobic contacts in the ATP-binding site.
As a result that is almost fully accommodated in the ATP-binding site of the
d746-750/T790M/C797S mutant, only small substituents would be allowed for derivatizations to
optimize the inhibitory activity. On the other hand, the terminal phenolic moiety of is directed to a
2 in the ATP-binding pocket may be promoted
-
2
2
1
2
vacant peripheral binding pocket consisting of Val726, Lys745, Met790, Thr854, and Asp855 (Figure 5).
This sub-binding region may serve as a potential target for improving both the potency and selectivity
in the inhibition of deregulated EGFR mutants because it includes the amino-acid residues not only in
the hinge region (Met790) and Gly loop (Val726) but also in the DFG motif (Asp855-Phe856-Gly857)
that resides on the activation loop. Therefore, the introduction of a suitable chemical moiety at the
terminal phenolic moiety of
triple mutant.
2 would have the effect of enhancing the biochemical potency against the
2.2. Synthesis of the Derivatives of 1 and 2 Generated from de novo Design
Virtual screening and the subsequent de novo design processes generated a variety of
fourth-generation EGFR inhibitors with
synthesized as illustrated in Scheme 1. The key intermediates
of benzofuran-3(2H)-one with paraformaldehyde and various secondary amines. Subsequently,
1
and
2
as the molecular core. Aurone derivatives
C were
B
were prepared by Mannich reaction
A
base-catalyzed condensation of B with aldehyde gave rise to the desired aurone derivatives C.
Scheme 1. Preparation of aurone derivatives: Reagents and conditions: (i) paraformaldehyde, EtOH,
reflux, 12 h; (ii) Piperidine (0.1 equiv.), MeOH, 2 h, 60 ◦C.
Quinazoline derivatives
addition of requisite amines to 2,4-dichloroquinazoline
the C4 position of quinazolines . Next, Suzuki Miyaura coupling reactions between intermediate D
E
were prepared as outlined in Scheme 2. Base-promoted nucleophilic
C
led to the installation of the amino groups at
D
−
with various arylboronic acids or arylboronic acid pinacol esters yielded target compound E.
2.3. Biochemical Potencies of the Newly Synthesized Compounds
Most initial hit compounds derived from virtual and experimental screening tend to be insufficient
in both biochemical potency and selectivity to serve as a good lead compound because all the candidate
molecules were prepared for the purposes other than inhibiting the target protein of interest. Hence,
we performed de novo design to identify the fourth-generation EGFR inhibitors better than 1 using

Int. J. Mol. Sci. 2020, 21, 9323
9 of 23
this compound as the molecular core. Based on the calculated binding mode of
1
(Figure 5), the
derivatizations were conducted so as to maximize the interactions with Ser797 and the amino-acid
residues in the peripheral binding pocket. Table 2 lists the chemical structures and IC50 data of the
seven derivatives of
Biochemical potencies for both the wild type and the triple mutant appear to remain almost intact as
the methyl group on the terminal piperidine ring of is removed in or shifted to the neighboring
carbons in and . Further substitution of the methoxy moiety in causes a substantial loss of
1 with respect to the d746-750/T790M/C797S mutant and the wild type of EGFR.
1
5
6
7
8
inhibitory activity, confirming that a bulky substituent on the benzofuran ring would be disfavored
for tight binding to EGFR. In contrast to the negligible substitution effects on the terminal piperidine
ring, the replacement of piperidine in
5 with piperazine in 9 leads to the increase in the inhibitory
activity by a factor of 3 with respect to both target proteins. Although a negative effect of the methoxy
substitution is also observed in 10, the biochemical potency against the triple mutant increases further
to the submicromolar level due to the introduction of -OH moiety in 11 on the benzofuran ring of 9.
However, the loss of selectivity over the wild-type EGFR makes it difficult for 11 to serve as a good
lead for the development of a new anti-NSCLC medicine.
Scheme 2. Preparation of the derivatives E. Reagents and conditions: (i) RNH2 or ROH, Et3N, THF, rt,
12-20 h; (ii) Pd(PPh3)4, ArB(OH)2 or ArBPin, aq Na2CO3, DME, 1 h, µW, 150 ◦C.
As a result that it was unsuccessful to derive the effective fourth-generation EGFR inhibitors by the
derivatizations of
Based on the structural features derived from docking simulations between the d746-750/T790M/C797S
mutant and , the structural modifications aimed at finding the optimal chemical moiety (R1) attached
1, the alternative de novo designs were carried out using 2 as a new molecular core.
2
to the nitrogen of the central quinazolin-4-amine group. The para position (R2) of the terminal phenol
group was also selected as the substitution point because its importance in EGFR inhibition was
demonstrated in the previous study [27]. Actually, only small substituents are allowed at the R2
position because the terminal phenyl ring of
Met790, and Thr854 in the ATP-binding site (Figure 5). Among the ten derivatives of
2
resides in close proximity to the side chains of Val726,
designed as
2
new fourth-generation EGFR inhibitors, two candidates exhibited not only the low nanomolar activity
but also high selectivity in the inhibition of the triple mutant over the wild type by a factor of more
than 104.
Summarized in Table 3 are the IC50 values of various derivatives of
2 generated from de novo
design with respect to the d746-750/T790M/C797S mutant and the wild type of EGFR. All derivatives
reveal the higher biochemical potency against the triple mutant than against the wild type. This
exemplifies the usefulness of the modified scoring function adopted in this work for optimizing the
activities of the fourth-generation EGFR inhibitors as well as for identifying the molecular cores of
potent inhibitors in virtual screening. Although the introduction of N,N-diethylpropan-1-amine (12
and 4-methylthiazole (14) moiety at the R1 position leads to only a slight increase in the inhibitory
activity against the triple mutant, the biochemical potency increases to the submicromolar level by
further substitution of a nitrile group at the R2 position in 13 and 15. The submicromolar inhibitory
activity is retained in the presence of 3-methylpyrrole (16) and 4-methyloxazole (17) at the R1 position.
Most remarkably, the replacement of the five-membered aromatic ring with imidazole (18) lead to the
increase in the biochemical potency to low-nanomolar level with more than 6690-fold higher activity
against the d746-750/T790M/C797S mutant than against the wild-type EGFR. The selectivity index
)

Int. J. Mol. Sci. 2020, 21, 9323
10 of 23
surges to higher than 104 either by the methyl substitution at the nitrogen atom of the imidazole
ring (19) or by the one-carbon elongation of the linking group in 20 between the central quinazoline
and the terminal imidazole ring. The change of R2 substituent from nitrile in 19 to aldehyde in 21
leads to a substantial loss of selectivity in contrast to the maintenance of low-nanomolar inhibitory
activity against the triple mutant, which confirms the necessity of the former to retain both biochemical
potency and selectivity. Among the ten derivatives of 2 listed in Table 3, 18–20 may be proposed as new
promising fourth-generation EGFR inhibitors in the context of the exceptionally high selectivity and
low-nanomolar activity in the inhibition of the d746-750/T790M/C797S mutant. They are anticipated
to serve as a good starting point for the development of new medicines against NSCLC cells with
acquired resistance to second- and third-generation EGFR inhibitor drugs.
Table 2. Structures and biochemical potencies (IC50 values in
µM) of the derivatives of 1 with respect
to the d746-750/T790M/C797S mutant and the wild type of EGFR a.
X b
EGFRd746-750/T790M/C797S
Y
EGFR
Selectivity
1
5
6
7
H
72.7 ± 6.8
2.11 ± 0.31
34.5
H
H
H
68.7 ± 3.4
65.7 ± 6.0
78.7 ± 4.6
3.01 ± 0.73
1.94 ± 0.35
5.29 ± 1.80
22.8
33.9
14.8
8
9
OCH3
H
>100
20.1 ± 7.2
1.10 ± 0.36
1.63 ± 0.43
>4.98
13.1
22.6
1.45
21.3 ± 6.3
36.8 ± 3.9
1.04 ± 0.16
10
11
OCH3
OH
0.715 ± 0.242
a
b
Values are given by the mean
the position of substitution.
±
standard deviations of two experiments. Asterisk indicates the atom attached to
To find a rationale for the exceptionally high selectivity and biochemical potency, the binding
modes of 19 and 20 were explored with docking simulations in the ATP-binding site of the
d746-750/T790M/C797S mutant. The calculated binding configurations of the two nanomolar inhibitors
are compared in Figure 6. Both 19 and 20 are supposed to be well accommodated in the ATP-binding
site in the similar way to
2 (Figure 5) with the nitrile moiety occupying the peripheral binding pocket.
This additional interaction would contribute to the increase in selectivity as well as in the inhibitory

Int. J. Mol. Sci. 2020, 21, 9323
11 of 23
activity in going from
2
to 19 and 20 (Table 3) because the peripheral binding pocket involves the
mutated residue Met790.
Table 3. Structures and biochemical potencies (IC50 values in
µ
M) of derivatives of
2
with respect to
the d746-750/T790M/C797S mutant and the wild type of EGFR a.
R1 b
EGFRd746-750/T790M/C797S
R2
EGFR
Selectivity
2
H
37.1 ± 2.5
1.73 ± 0.43
21.4
12
H
>50
0.516 ± 0.206
>96.9
13
14
CN
8.45 ± 1.89
0.0265 ± 0.0084
319
H
>50
1.04 ± 0.07
>50
1.12 ± 0.21
0.715 ± 0.092
0.0721 ± 0024
0.593 ± 0.076
>44.6
1.45
15
16
17
CN
CN
CN
>693
>84.3
>50
18
19
CN
CN
>50
>50
0.00747 ± 0.00039
>6693
0.00338 ± 0.00102
0.00484 ± 0.00063
>14793
20
21
CN
>50
>10331
CHO
0.935 ± 0.173
0.00793 ± 0.00168
118
a
b
Values are given by the mean
the position of substitution.
±
standard deviations of two experiments. Asterisk indicates the atom attached to
It is interesting to note that the terminal 1-methylimidazole group of 19 forms a close van der
Waals contact with the sidechain phenyl ring of Phe723 in the Gly loop. This interaction would also
be a significant contributor to the impairment of the kinase activity of the EGFRd746-750/T790M/C797S
because the Gly loop acts as a receptor for binding of the phosphate group in complexation with ATP.
The extra stabilization of the EGFRd746-750/T790M/C797S
-20 complex seems to be caused by the additional
hydrogen-bond interaction of the terminal imidazole moiety with the side-chain carboxylate group
of Asp855, which is a component of the DFG motif (Asp855-Phe856-Gly857) on the activation loop.
This new hydrogen bond is made possible by one-carbon elongation of the linking group to connect

Int. J. Mol. Sci. 2020, 21, 9323
12 of 23
the central quinazoline ring and the terminal imidazole group, which is required to reach Asp855
that resides at the end of the ATP-binding pocket. In the calculated EGFRd746-750/T790M/C797S
19 and
EGFRd746-750/T790M/C797S
20 complexes, it is also worth noting that both the hydrophobic interaction of
-
-
19 with Phe723 and the hydrogen bond of 20 with Asp855 are supported by the neighboring hydrogen
bond with the side-chain hydroxyl moiety of mutated residue Ser797. The additional interactions
generated by the chemical modification from
2 to 19 and 20 are thus consistent with the substantial
increase in the inhibitory activity and selectivity.
Figure 6. Calculated binding modes of 19 and 20 in the ATP-binding site of d746-750/T790M/C797S
mutant EGFR. Carbon atoms of 19 20, and EGFR are colored in green, black, and cyan, respectively.
,
Hydrogen bonds are indicated with dotted lines. The red dotted circle indicates the small peripheral
binding pocket near the hinge region.
Two promising molecules (18 and 19) were further evaluated for cellular growth inhibition against
Ba/F3 cell lines with the wild type and the d746-750/T790M/C797S mutant EGFR. These cell-based
assays were conducted at WuXi AppTec Corp. (Shanghai, China) using Gefitinib and Brigatinib as the
reference compounds, which were approved by FDA for the NSCLC therapy. Only the two molecules
were investigated because of the difficulty in synthesizing 20 and 21 in the amount sufficient to perform
cellular studies. As shown in Table 4, both 18 and 19 revealed high antiproliferative activity against
the d746-750/T790M/C797S mutant cell at the submicromolar level. However, the micromolar-level
inhibitory activity was also observed for the cell lines with the wild-type EGFR to the extent similar
to the reference compounds. As a result that the anticellular activity appears to be higher than
the inhibitory activity in enzyme assays (Table 3), further optimization would be required for the
fourth-generation EGFR inhibitors found in this work to alleviate the potential off-target activity.
Although some promising fourth-generation EGFR inhibitors were identified in this work,
the biochemical potencies of many compounds in Tables 1–3 remained modest in spite of the
modification of the scoring function for virtual screening and de novo design. The imperfection of the
scoring function can be attributed in a large part to the incomplete optimization of the weighting factors
for varying energy terms, which stems from the insufficient number of EGFR-inhibitor complexes in
the training set for parameterizations. The scoring function is expected to become even more accurate

Int. J. Mol. Sci. 2020, 21, 9323
13 of 23
by reoptimizing the weighting factors using the new training set supplemented with a variety of
EGFR-inhibitor complexes. In the near future, we plan to design and identify the more potent and
selective fourth-generation EGFR inhibitors than those presented in this work with the improved
scoring function.
Table 4. Antiproliferative activities of 18 and 19 in wile-type and mutant Ba/F3 cell lines a.
IC50 (µM)
Compound
Selectivity
Ba/F3d746-750/T790M/C797S
Ba/F3
18
19
>5
0.78 ± 0.31
0.74 ± 0.22
1.50 ± 0.36
0.067 ± 0.014
>6.41
3.34
2.48
23.3
2.47 ± 0.89
3.72 ± 1.17
1.56 ± 0.45
Gefitinib
Brigatinib
a
Values are given by the mean ± standard deviations of two experiments.
3. Materials and Methods
3.1. Structural Preparations of d746-750/T790M/C797S Mutant and Wild Type of EGFR
As a result that the 3D structure of d746-750/T790M/C797S mutant EGFR was unavailable in
Protein Data Bank (PDB), its atomic coordinates were constructed by homology modeling using the
active conformation of the L858R/T790M/C797S mutant [28] as the structural template (PDB entry:
6JRJ). This homology modeling began with the retrieval of the amino acid sequence of human EGFR
comprising 1210 residues from UniProtKB protein knowledgebase (http://www.uniprot.org, accession
number: P00533, gene name: EGFR ERBB). Only the cytoplasmic kinase domain (residues 700-1014)
of EGFR was considered in the homology modeling because the present study was focused on the
discovery of ATP-competitive inhibitors. To build the structure of the d746-750/T790M/C797S mutant,
the atomic coordinates were optimized in such a way as to minimize the violation of spatial restraints
as implemented in the latest version of the MODELLER program [41].
The X-ray crystal structure of the EGFR kinase domain in the active form [42] (PDB entry: 2GS2)
was selected as the receptor model for the wild type. Finally, all-atom models of the wild type and
d746-750/T790M/C797S mutant were constructed by adding the hydrogen atoms according to the
protonation states of titratable residues revealed in the patterns of intramolecular hydrogen bonds.
3.2. Two-Track Virtual Screening to Identify the Fourth-Generation EGFR Inhibitors
To identify the EGFR inhibitors specific for the d746-750/T790M/C797S mutant, virtual screening
should be conducted not only for the triple mutant but also for the wild-type EGFR to collect the
candidates capable of binding tightly and weakly to the former and the latter, respectively. This two-track
virtual screening started with the preparation of a docking library containing approximately 370,000
synthetic and natural compounds from the latest version of the chemical database provided by
InterBioScreen Ltd. A total of 560,000 compounds in the database were filtered to collect only those that
possess the physicochemical properties of drug candidates [35]. Similar molecules with the Tanimoto
coefficient exceeding 0.8 were then clustered into a single representative molecule to remove structural
redundancy. After the two filtration steps, 3D atomic coordinates of all the molecules in the docking
library were generated with the CORINA program [43].
Two-track virtual screening to identify fourth-generation EGFR inhibitors was performed with
the automated AutoDock program [44
,45], the performance of which had been appreciated in the
discovery of various kinase inhibitors [46
–48]. Despite the significant contribution to protein–ligand
binding affinity, it is difficult to precisely reflect the ligand hydration effects in docking simulations for
virtual screening because the scoring function of the original AutoDock program encompasses a crude
dehydration energy term involving only six atom types to describe varying solute molecules. As a
preliminary step to virtual screening of fourth-generation EGFR inhibitors, the scoring function was

Int. J. Mol. Sci. 2020, 21, 9323
14 of 23
modified by substituting a new ligand dehydration energy term for the original one. This modified
scoring function (∆Gbaq) has the following mathematical form.
!
!
P
P
P
P
Aij
Bij
r6ij
Cij
Dij
∆Gabq = WvdW
−
+ Whbond
E(t)
−
12
12
10
r
r
r
ij
ij
ij
i = 1 j = 1
i = 1 j = 1


2
(1)
r






ij
P
P
P
P
qiqj
Vje−

max

2
2σ
+Welec
+ WtorNtor
+
S O
−
i




ε(rij)rij
i

i = 1 j = 1
i = 1
j,i
The coefficients WvdW, Whbond, Welec, and Wtor in Equation (1) refer to the weighting factors of
van der Waals interactions, hydrogen bonds, electrostatic interactions, and torsional motions of the
putative inhibitor, respectively. The variable rij represents the interatomic separation, and the Aij, Bij,
Cij, and Dij parameters are associated with the well depth and the equilibrium distance in a given
potential energy function. AMBER force field parameters were adopted to compute the van der Waals
interaction energies between EGFR and all putative inhibitors. An additional weighting factor (E(t))
was necessary in the intermolecular hydrogen bond term to reflect the angle-dependent directionality.
In calculating the intermolecular electrostatic interactions between EGFR and a putative inhibitor, we
used the atomic charges determined with Gasteiger–Marsilli method [49] and the distance-dependent
sigmoidal function as the dielectric constant to simulate the long-range charge screening effects [50].
The Ntor parameter in the torsional term means the number of rotatable bonds to estimate the entropic
penalty for a putative inhibitor to be bound in the ATP-binding site of EGFR.
The first four terms in Equation (1) correspond to the binding free energy in the gas phase,
while the final term is the negative of ligand hydration free energy. In this energy term, the Si, Vi, and
Oimax parameters denote the atomic hydration energy per unit volume, the atomic volume in molecules,
and the atomic maximum occupancy, respectively [51]. To quantify the hydration free energies of
putative EGFR inhibitors, all atomic parameters were derived with the extended solvent-contact model
that had achieved high outperformance in the SAMPL4 blind prediction challenge for molecular
hydration free energies [52,53]. The introduction of this sophisticated hydration free energy term in the
scoring function would enhance the possibility of finding actual EGFR inhibitors in virtual screening
by preventing the overestimation of the biochemical potency of a candidate molecule with many polar
groups [31]. Actually, the virtual screening protocol was not validated explicitly in this work because
the accuracy of the modified scoring function was demonstrated well in the previous studies [47,48].
3.3. De novo Design
To improve the potency and selectivity in inhibiting the d746-750/T790M/C797S mutant, the hit
compounds identified from virtual screening needed to be structurally modified in such a way as to
maximize the interactions in the ATP-binding site. For this purpose, the structure-based de novo design
was performed in a stepwise fashion. First, various derivatives of a hit compound were generated with
the LigBuilder program [54] using the structure of d746-750/T790M/C797S mutant in complex with
the hit compound as the starting structure. This step proceeded with the genetic algorithm to change
the structure of the molecular core by introducing a variety of substituents at the specified positions.
The number of such substitution positions was limited to two in this study to reduce the computational
burden. The empirical scoring function comprising electrostatic, van der Waals, hydrogen bond,
and entropic terms was then used for selecting approximately 14,000 derivatives that were predicted
to have a higher binding affinity than the initial hit. Bioavailability rules were also applied in this step
to collect only the derivatives with druggable physicochemical properties.
The second step of de novo design was performed in a similar manner to the precedent two-track
virtual screening in the context that all of the derivatives were further screened to select only those with
a higher binding affinity for the d746-750/T790M/C797S mutant than for the wild type. The modified
scoring function in Equation (1) served to evaluate the derivatives designed in the first step. Among
the derivatives predicted to bind more tightly to the triple mutant than the wild type, those with the

Int. J. Mol. Sci. 2020, 21, 9323
15 of 23
difference in binding free energies larger than 5 kcal/mol were inspected for the availability of chemical
synthesis. Finally, seven and ten derivatives of and were synthesized and evaluated, respectively,
1
2
with enzyme inhibition assays to find the new fourth-generation EGFR inhibitors.
3.4. Chemical Synthesis
3.4.1. General Methods
Unless stated otherwise, reactions were performed in flame-dried glassware. Analytical thin layer
chromatography (TLC) was performed on precoated silica gel 60 F254 plates and visualization on TLC
was achieved by UV light (254 and 365 nm). Flash column chromatography was performed on silica
gel (400–630 mesh) or a CombiFlash® Rf+ system with RediSep® Rf silica columns (230–400 mesh)
using a proper eluent. 1H NMR was recorded on Brucker Avance 400 MHz, Brucker Avance Neo
500 MHz, or Agilent Technologies DD2 600 MHz. Chemical shifts were quoted in parts per million
(ppm) referenced to the appropriate solvent peak or 0.0 ppm for tetramethylsilane. The following
abbreviations were used to describe peak splitting patterns when appropriate: br = broad, s = singlet,
d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, dd = doublet of doublet, td = triplet of
doublet, ddd = doublet of doublet of doublet. Coupling constants, J, were reported in hertz unit (Hz).
13C NMR was recorded on Brucker Avance 100 MHz or Agilent Technologies DD2 150 MHz, and fully
decoupled by broad band proton decoupling. Chemical shifts were reported in ppm referenced to the
centerline of a triplet at 77.16 ppm of CDCl3-d septet at 39.52 ppm of DMSO-d6, or quintet at 53.84
of CD2Cl2-d2. High-resolution mass spectra were obtained by using EI or FAB method from Korea
Basic Science Institute (Daegu). Commercial grade reagents and solvents were used without further
purification except as indicated below.
3.4.2. Synthesis of Compound C
Generally, aurone derivatives were synthesized via two steps as depicted in Scheme 1. At the
first step, piperidine derivatives or Boc protected piperazine were introduced to a coumaranone core
with methylene unit using paraformaldehyde. To the corresponding modified coumaranone core,
benzofuran-2-carbaldehyde was introduced by condensation reaction under catalytic amount of base.
Further deprotection processes were employed to afford more aurone derivatives using HCl or BBr3.
3.4.3. Representative Procedure for Modification of Coumaranone (Step 1)
Reaction was conducted in a round bottom flask (15 mL) sealed with a rubber septa.
6-Hydroxy-3-coumaranone (100 mg, 0.67 mmol) and paraformaldehyde (20 mg, 0.67 mmol) were
combined. To the mixture, 3 mL ethanol and 3-Methylpiperidine (78 mg, 0.67 mmol) were added.
The mixture was heated and stirred under reflux at 80 ◦C for overnight. The reaction mixture was
monitored by TLC using 95% dichloromethane and 5% methanol as the mobile phase. After 24 h,
the reaction mixture was concentrated and diluted with dichloromethane (25 mL
×
3) and washed
with brine (50 mL). The organic layer was dried over Na2SO4. After removal of solvent, concentrated
mixture was purified by flash chromatography on silica gel (dichloromethane/methanol = 20:1) to give
the desired product (35 mg, 20%, white solid).
3.4.4. Representative Procedure for Preparing Aurone Derivatives (Step 2)
Reaction was conducted in a round bottom flask (15 mL) sealed with a rubber septa.
6-Hydroxy-7-((3-methylpiperidin-1-yl)methyl)benzofuran-3(2H)-one (35 mg, 0.13 mmol) was dissolved
in 3 mL methanol. Benzofuran-2-carbaldehyde (19 mg, 0.13 mmol) and catalytic amount piperidine
(1.1 mg, 0.013 mmol) were added to the solution. The mixture was heated and stirred for 2 h at 60 ◦C.
The reaction mixture was monitored by TLC using 95% dichloromethane and 5% methanol as the
mobile phase. After 2 h, the reaction mixture was concentrated under reduced vacuum, and purified

Int. J. Mol. Sci. 2020, 21, 9323
16 of 23
by flash chromatography on silica gel (dichloromethane/methanol = 20:1) to give the desired product
compound (35 mg, 68%, yellow solid).
(Z)-2-(benzofuran-2-ylmethylene)-6-hydroxy-7-(piperidin-1-ylmethyl)benzofuran-3(2H)-one (5). Prepared
according to general procedure started with 0.67 mmol 6-hydroxy-3-coumaranon to afford the title
compound (38 mg, 23%, yellow oil for step 1 using piperidine, and 12 mg, 14%, yellow solid for step 2
started with 0.23 mmol modified coumaranone derived from step 1 and benzofuran-2-carbaldehyde);
1H NMR (400 MHz, Chloroform-d)
J = 8.4, 1.0 Hz, 1H), 7.43–7.38 (m, 1H), 7.33–7.29 (m, 2H), 6.90 (s, 1H), 6.76 (d, J = 8.5 Hz, 1H), 4.13 (s,
2H), 2.96 (br, 6H), 1.82 (br, 4H); 13C NMR (100 MHz, Chloroform-d)
181.7, 168.7, 165.6, 155.4, 150.6,
δ 7.69 (dd, J = 7.8, 1.2 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.55 (dd,
δ
148.4, 128.8, 126.0, 125.2, 123.4, 121.5, 114.1, 113.0, 111.5, 111.5, 104.1, 99.8, 54.3, 54.0, 25.6, 23.6; HRMS
(EI) m/z calcd. for C23H21NO4+ [M]+: 375.1471, found: 375.1473.
(Z)-2-(benzofuran-2-ylmethylene)-6-hydroxy-7-((3-methylpiperidin-1-yl)methyl)benzofuran-3(2H)-one
(6). Prepared according to general procedure started with 0.67 mmol 6-hydroxy-3-coumaranon to
afford the title compound (35 mg, 20%, white solid for step 1 using 3-methylpiperidine, and 35 mg,
68%, yellow solid for step 2 started with 0.15 mmol modified coumaranone derived from step 1 and
benzofuran-2-carbaldehyde); 1H NMR (500 MHz, Chloroform-d)
δ 7.67–7.64 (m, 1H), 7.60 (d, J = 8.5
Hz, 1H), 7.52 (d, J = 8.2 Hz, 1H), 7.36 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 7.28 (d, J = 7.2 Hz, 2H), 6.86 (s, 1H),
6.66 (d, J = 8.4 Hz, 1H), 4.04 (s, 2H), 3.19–2.98 (m, 2H), 2.30 (br, 1H), 2.01 (br, 1H), 1.88–1.77 (m, 3H),
1.76–1.66 (m, 1H), 1.04 (s, 1H), 0.94 (d, J = 6.4 Hz, 3H); 13C NMR (125 MHz, Chloroform-d)
δ 181.9, 168.6,
165.8, 155.6, 150.7, 148.5, 128.9, 126.1, 125.4, 123.5, 121.7, 114.1, 113.3, 111.7, 111.6, 104.2, 100.0, 77.4, 61.0,
54.0, 53.6, 32.3, 25.4, 19.5; HRMS (EI) m/z calcd. for C24H23NO4+ [M]+: 389.1627, found: 389.1626.
(Z)-2-(benzofuran-2-ylmethylene)-6-hydroxy-7-((4-methylpiperidin-1-yl)methyl)benzofuran-3(2H)-one
(7). Prepared according to general procedure started with 0.67 mmol 6-hydroxy-3-coumaranon to
afford the title compound (17 mg, 10%, red oil for step 1 using 4-methylpiperidine, and 19 mg, 73%,
yellow solid for step 2 started with 0.065 mmol modified couramanone derived from step 1 and
5-methoxybenzofuran-2-carbaldehyde); 1H NMR (400 MHz, Chloroform-d)
δ 7.67 (d, J = 7.8 Hz, 1H),
7.60 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.41–7.33 (m, 1H), 7.28 (q, J = 4.1, 3.1 Hz, 2H), 6.87 (s,
1H), 6.65 (d, J = 8.5 Hz, 1H), 4.05 (s, 2H), 3.23–3.02 (m, 2H), 2.47–2.25 (m, 2H), 1.87–1.73 (m, 2H), 1.55
(br, 1H), 1.45–1.31 (m, 2H), 1.00 (d, J = 6.4 Hz, 3H); 13C NMR (101 MHz, Chloroform-d)
δ 181.8, 168.6,
165.7, 155.5, 150.7, 148.5, 128.9, 126.1, 125.3, 123.5, 121.7, 114.1, 113.2, 111.6, 111.6, 104.3, 99.9, 53.9, 53.7,
34.0, 30.4, 21.7; HRMS (FAB) m/z calcd. for C24H24NO4+ [M]+: 390.1700, found: 390.1709.
(Z)-6-hydroxy-2-((5-methoxybenzofuran-2-yl)methylene)-7-((3-methylpiperidin-1-yl)methyl)benzofuran
-3(2H)-one (8). Prepared according to general procedure started with 0.67 mmol
6-hydroxy-3-coumaranonwith to afford the title compound (35 mg, 20%, white solid for step
1 using 3-methylpiperidine, and 12 mg, 52%, yellow solid for step 2 started with 0.015 mmol modified
coumaranone derived from step 1 and 5-methoxybenzofuran-2-carbaldehyde); 1H NMR (400 MHz,
Chloroform-d)
δ 7.64 (dd, J = 8.4, 2.2 Hz, 1H), 7.45 (dd, J = 8.9, 2.2 Hz, 1H), 7.31 (d, J = 2.3 Hz, 1H), 7.13
(d, J = 2.5 Hz, 1H), 7.01 (dt, J = 9.0, 2.5 Hz, 1H), 6.88 (d, J = 2.2 Hz, 1H), 6.68 (dd, J = 8.5, 2.2 Hz, 1H),
4.05 (d, J = 2.2 Hz, 2H), 3.91 (s, 3H), 3.24–2.98 (m, 2H), 2.32 (br, 1H), 2.03 (br, 1H), 1.90–1.82 (m, 3H),
1.79–1.68 (m, 1H), 1.07 (br, 1H), 0.99 (d, J = 5.4 Hz, 3H); 13C NMR (100 MHz, Chloroform-d)
δ 181.9,
168.7, 165.6, 156.4, 151.4, 150.8, 148.3, 129.5, 125.3, 115.6, 114.1, 113.2, 112.2, 111.8, 104.3, 103.2, 100.1,
+
77.4, 61.1, 56.0, 54.3, 53.7, 32.3, 31.4, 19.5; HRMS (FAB) m/z calcd. for C25H26NO5 [M]+: 420.1805,
found: 420.1809.
(Z)-2-(benzofuran-2-ylmethylene)-6-hydroxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one (9).
Prepared according to following steps: step 1 started with 0.67 mmol 6-hydroxy-3-coumaranon
and tert-butyl piperazine-1-carboxylate to afford a desired intermediate (100 mg, 43%, white

Int. J. Mol. Sci. 2020, 21, 9323
17 of 23
solid), and step 2 started with the 0.15 mmol modified coumaranone derived from step 1 and
benzofuran-2-carbaldehyde to afford a corresponding aurone derivative (40 mg, 58%, yellow solid).
0.063 mmol of desired product of step 2 was used for a next reaction with 2.8 mL of 4 M HCl in
dioxane solution and 2.8 mL dichloromethane as a solvent. Reaction mixture was stirred for 2 h at
room temperature. Precipitated yellow solid was collected by filtration, washed with water, and dried
in vacuum to afford the tittle compound (23 mg, 97%, yellow solid); 1H NMR (400 MHz, DMSO-d6)
9.82 (s, 2H), 7.85 (d, J = 7.7 Hz, 1H), 7.80–7.74 (m, 2H), 7.46–7.38 (m, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.09 (d,
J = 8.6 Hz, 1H), 6.94 (s, 1H), 4.47 (s, 2H), 3.61 (br, 4H), 3.43 (br, 4H); 13C NMR (100 MHz, DMSO-d6)
δ
δ
180.7, 167.1, 166.2, 155.1, 151.3, 149.6, 147.1, 128.5, 127.3, 126.6, 123.6, 122.4, 113.3, 112.9, 112.8, 111.6,
99.8, 47.8, 47.5, 40.3; HRMS (EI) m/z calcd. for C22H20N2O4+ [M]+: 376.1423, found:376.1421.
(Z)-6-hydroxy-2-((5-methoxybenzofuran-2-yl)methylene)-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one
(10). Prepared according to following steps: step 1 started with 0.67 mmol 6-hydroxy-3-coumaranon
and tert-butyl piperazine-1-carboxylate to afford a desired intermediate (100 mg, 43%, white solid),
and step 2 started with the 0.15 mmol modified coumaranone derived from step 1 and
5-methoxybenzofuran-2-carbaldehyde to afford a corresponding aurone derivative (35 mg, 69%,
yellow solid). 0.039 mmol of desired product of step 2 was used for a next reaction with 0.043 mL 1 M
BBr3 in dichloromethane solution with 1 mL of dichloromethane solvent. The mixture was stirred
for 50 h at 0 ◦C which was changed to room temperature slowly. After reaction followed by basic
extractive work up, crude was purified with recrystallization using methylene chloride and hexane
1
to afford the title compound (13 mg, 48%, orange solid); H NMR (400 MHz, DMSO-d6)
δ 7.53 (d,
J = 8.9 Hz, 1H), 7.40–7.34 (m, 2H), 7.25 (d, J = 2.6 Hz, 1H), 6.98 (dd, J = 9.0, 2.7 Hz, 1H), 6.58 (s, 1H),
6.38 (d, J = 8.6 Hz, 1H), 3.85 (s, 2H), 3.82 (s, 3H), 2.98 (br, J = 5.0 Hz, 4H), 2.74 (br, J = 5.0 Hz, 4H); 13
C
NMR (126 MHz, DMSO-d6)
δ 181.7, 167.0, 155.9, 151.5, 149.5, 129.3, 124.5, 117.1, 116.4, 114.8, 111.7,
+
110.4, 105.2, 103.4, 98.9, 96.0, 83.2, 55.6, 50.4, 49.9, 43.8; HRMS (FAB) m/z calcd. for C23H23N2O5 [M]+:
407.1601, found: 407.1611.
(Z)-6-hydroxy-2-((5-hydroxybenzofuran-2-yl)methylene)-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one
(11). Prepared according to following steps: step 1 started with 0.67 mmol 6-hydroxy-3-coumaranon
and tert-butyl piperazine-1-carboxylate to afford a desired intermediate (100 mg, 43%, white
solid), and step 2 started with the 0.15 mmol modified coumaranone derived from step 1 and
5-methoxybenzofuran-2-carbaldehyde to afford a corresponding aurone derivative (35 mg, 49%, yellow
solid). 0.069 mmol of desired product of step 2 was used for a next reaction with 0.69 mL 1 M BBr3 in
dichloromethane solution with 1 mL of dichloromethane solvent. The mixture was stirred for 24 h at
0 ◦C which was changed to room temperature slowly. After reaction followed by basic extractive work
up, crude was purified with flash chromatography on silica gel (dichloromethane/0.05 M ammonia
1
in methanol = 10: 1) to afford the title compound (13 mg, 48%, orange solid); H NMR (400 MHz,
DMSO-d6)
1H), 6.50 (s, 1H), 6.30 (d, J = 8.6 Hz, 1H), 3.82 (s, 2H), 3.17 (s, 1H), 2.94 (t, J = 4.9 Hz, 4H), 2.70 (t,
J = 4.9 Hz, 4H); 13C NMR (100 MHz, DMSO-d6)
178.0, 167.6, 154.1, 151.8, 150.3, 149.3, 129.9, 124.9,
δ 7.40 (d, J = 8.8 Hz, 1H), 7.33–7.25 (m, 2H), 7.00 (d, J = 2.5 Hz, 1H), 6.82 (dd, J = 8.8, 2.5 Hz,
δ
122.5, 117.4, 115.3, 111.8, 110.3, 107.3, 105.9, 105.6, 96.2, 51.2, 50.4, 44.4; HRMS (EI) m/z calcd. for
C22H20N2O5+ [M]+: 392.1372, found: 392.1373.
3.4.5. Synthesis of Compound E
Triethylamine (0.841 mL, 6.03 mmol) and 3-picolylamine (0.563 mL, 5.53 mmol) were added to a
solution of 2,4-dichloroquinazoline (1.0 g, 5.03 mmol) in tetrahydrofuran (13 mL). The mixture was
stirred at room temperature. After completion of conversion, the reaction mixture was concentrated in
vacuo, dissolved with CH2Cl2 (25 mL) and washed with distilled water (10 mL
was dried over MgSO4 and the solvent was evaporated. Resulting residue was purified by filtration
×
3). The organic layer
washed by n-hexanes to obtain the intermediate.

Int. J. Mol. Sci. 2020, 21, 9323
18 of 23
The mixture of aforementioned intermediate (0.185 mmol), 2-hydroxyphenylboronic acid (30 mg,
0.222 mmol), Pd(PPh3)4 (21.3 mg, 0.019 mmol), and 2 M aqueous Na2CO3 (0.185 mL, 0.370 mmol)
in 1,2-dimethoxyethane (0.5 mL) was added in a 10 mL microwave vial and heated at 150 ◦C under
microwave irradiation. After 1 h, distilled water (10 mL) was added to the cooled reaction mixture and
extracted with CH2Cl2 (25 mL
MgSO4 and the solvent was evaporated. The residue was purified by flash chromatography on silica
×
3) and washed with brine (50 mL). The organic layer was dried over
gel (CH2Cl2/MeOH = 40:1) to give the desired product compound.
2-(4-((3-(diethylamino)propyl)amino)quinazolin-2-yl)phenol (12). Prepared according to general
procedure, 2,4-dichloroquinazoline started to afford the title compound (51 mg, 85%, pale yellow solid);
1H NMR (400 MHz, DMSO-d6)
δ 14.77 (s, 1H), 8.82 (t, J = 5.3 Hz, 1H), 8.47 (dd, J = 8.2, 1.8 Hz, 1H), 8.26
(dd, J = 8.3, 1.3 Hz, 1H), 7.80 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H), 7.74 (dd, J = 8.3, 1.3 Hz, 1H), 7.53 (ddd,
J = 8.2, 6.8, 1.4 Hz, 1H), 7.36 (ddd, J = 8.2, 7.2, 1.8 Hz, 1H), 6.95–6.84 (m, 2H), 3.69 (q, J = 6.6 Hz, 2H),
2.72–2.52 (m, 6H), 2.00–1.77 (m, 2H), 0.99 (t, J = 7.1 Hz, 6H). 13C NMR (101 MHz, DMSO-d6)
δ 160.9,
160.8, 159.0, 146.7, 133.4, 132.4, 129.0, 126.1, 125.8, 122.9, 119.2, 118.1, 117.2, 113.5, 50.1, 46.3, 25.3, 11.2.
3-(4-((3-(diethylamino)propyl)amino)quinazolin-2-yl)-4-hydroxybenzonitrile (13). Prepared according to
general procedure, 2,4-dichloroquinazoline started to afford the title compound (5 mg, 8%, pale yellow
1
solid); H NMR (400 MHz, DMSO-d6)
δ 16.07 (s, 1H), 9.02 (s, 1H), 8.79 (d, J = 2.3 Hz, 1H), 8.32 (d,
J = 8.2 Hz, 1H), 7.89–7.82 (m, 2H), 7.79 (dd, J = 8.6, 2.2 Hz, 1H), 7.60 (ddd, J = 8.2, 6.6, 1.5 Hz, 1H), 7.09
(d, J = 8.6 Hz, 1H), 3.76 (d, J = 6.5 Hz, 2H), 2.75 (br, 6H), 1.94 (d, J = 25.9 Hz, 2H), 1.08 (s, 6H). 13C NMR
(126 MHz, DMSO-d6)
δ 165.4, 159.6, 159.6, 146.1, 136.1, 134.3, 133.9, 127.0, 126.3, 123.5, 120.1, 119.8,
119.5, 114.1, 100.8, 46.8.
2-(4-((thiazol-4-ylmethyl)amino)quinazolin-2-yl)phenol (14).
procedure, 2,4-dichloroquinazoline started to afford the title compound (42 mg, 70%, pale yellow solid);
1H NMR (400 MHz, DMSO-d6)
14.66 (s, 1H), 9.32 (s, 1H), 9.08 (s, 1H), 8.38 (dd, J = 8.4, 4.1 Hz, 2H),
7.83 (t, J = 7.6 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.60 (s, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.34 (t, J = 7.6 Hz,
1H), 6.89 (t, J = 6.7 Hz, 2H), 5.05 (d, J = 5.6 Hz, 2H). 13C NMR (151 MHz, DMSO-d6)
160.8, 160.7, 159.0,
Prepared according to general
δ
δ
152.0, 146.7, 137.7, 136.3, 133.6, 132.4, 129.1, 126.1, 125.9, 123.1, 119.1, 118.3, 117.2, 113.5, 36.7.
4-hydroxy-3-(4-((thiazol-4-ylmethyl)amino)quinazolin-2-yl)benzonitrile (15). Prepared according
to general procedure, 2,4-dichloroquinazoline started to afford the title compound (39 mg, 60%, pale
yellow solid); 1H NMR (400 MHz, DMSO-d6)
δ 15.83 (s, 1H), 9.45 (t, J = 5.6 Hz, 1H), 9.09 (d, J = 2.0 Hz,
1H), 8.66 (d, J = 2.3 Hz, 1H), 8.38 (d, J = 8.2 Hz, 1H), 7.88–7.82 (m, 1H), 7.82–7.78 (m, 1H), 7.74 (dd,
J = 8.5, 2.3 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.60–7.56 (m, 1H), 7.04 (d, J = 8.6 Hz, 1H), 5.06 (d, J = 5.6 Hz,
2H). 13C NMR (101 MHz, DMSO-d6)
δ 164.7, 159.2, 159.1, 154.3, 154.1, 145.9, 135.6, 133.9, 133.7, 126.6,
125.9, 123.2, 119.7, 119.3, 118.9, 115.5, 113.7, 100.5, 41.0.
3-(4-(((1H-pyrrol-3-yl)methyl)amino)quinazolin-2-yl)-4-hydroxybenzonitrile (16). Prepared according to
general procedure, 2,4-dichloroquinazoline started to afford the title compound (18 mg, 27%, yellow
1
solid); H NMR (400 MHz, DMSO-d6)
δ 16.08 (s, 1H), 10.65 (s, 1H), 9.17 (t, J = 5.6 Hz, 1H), 8.81 (t,
J = 1.9 Hz, 1H), 8.36 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.79 (s, 1H), 7.77 (s, 1H), 7.55 (t,
J = 7.6 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 6.82 (s, 1H), 6.71–6.57 (m, 1H), 6.13 (s, 1H), 4.74 (d, J = 5.6 Hz,
2H). 13C NMR (101 MHz, DMSO)
δ 165.0, 159.0, 158.8, 145.9, 135.6, 133.8, 133.5, 126.4, 125.9, 123.2,
119.8, 119.6, 119.5, 119.1, 117.8, 116.2, 113.8, 107.7, 100.4, 38.9.
4-hydroxy-3-(4-((oxazol-4-ylmethyl)amino)quinazolin-2-yl)benzonitrile (17). Prepared according to
general procedure, 2,4-dichloroquinazoline started to afford the title compound (58 mg, 88%, pale yellow
solid); 1H NMR (600 MHz, DMSO-d6)
δ
15.85 (s, 1H), 9.28 (t, J = 5.4 Hz, 1H), 8.71 (d, J = 2.2 Hz, 1H),
8.36 (s, 1H), 8.34 (d, J = 8.2 Hz, 1H), 8.07 (s, 1H), 7.84 (t, J = 7.7 Hz, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.75

Int. J. Mol. Sci. 2020, 21, 9323
19 of 23
(dd, J = 8.5, 2.2 Hz, 1H), 7.57 (t, J = 7.7 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 4.82 (d, J = 5.4 Hz, 2H). 13
NMR (151 MHz, DMSO-d6) 164.7, 159.1, 159.0, 152.1, 145.8, 137.1, 136.3, 135.6, 133.9, 133.6, 126.5,
125.9, 123.2, 119.6, 119.3, 118.7, 113.6, 100.5, 36.8.
C
δ
3-(4-(((1H-imidazol-4-yl)methyl)amino)quinazolin-2-yl)-4-hydroxybenzonitrile (18). Prepared according
to general procedure, 2,4-dichloroquinazoline started to afford the title compound (20 mg, 30%, pale
yellow solid); 1H NMR (400 MHz, DMSO-d6)
δ
15.98 (s, 1H), 11.92 (s, 1H), 9.25 (s, 1H), 8.78 (s, 1H), 8.38
(d, J = 8.3 Hz, 1H), 7.79 (dd, J = 21.6, 8.4 Hz, 3H), 7.58 (d, J = 15.2 Hz, 2H), 7.06 (d, J = 8.7 Hz, 2H),
4.81 (s, 2H). 13C NMR (101 MHz, DMSO-d6)
165.4, 159.5, 159.4, 146.3, 136.1, 135.4, 134.3, 134.1, 126.9,
δ
126.3, 123.7, 120.2, 119.9, 119.5, 114.2, 113.9, 100.9.
4-hydroxy-3-(4-(((1-methyl-1H-imidazol-4-yl)methyl)amino)quinazolin-2-yl)benzonitrile (19). Prepared
according to general procedure, 2,4-dichloroquinazoline started to afford the title compound (38 mg,
60%, pale yellow solid); 1H NMR (600 MHz, DMSO-d6)
δ 15.96 (s, 1H), 9.26 (t, J = 5.6 Hz, 1H), 8.78 (d,
J = 2.1 Hz, 1H), 8.38 (d, J = 8.3 Hz, 1H), 7.84 (t, J = 7.6 Hz, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.78 (dd, J = 8.7,
2.0 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.52 (s, 1H), 7.08 (s, 1H), 7.06 (d, J = 2.5 Hz, 1H), 4.78 (d, J = 5.6 Hz,
2H), 3.59 (s, 3H).13C NMR (151 MHz, DMSO-d6)
δ 164.9, 159.1, 158.9, 145.9, 138.6, 137.4, 135.6, 133.8,
133.7, 126.5, 125.9, 123.2, 119.8, 119.4, 118.9, 117.8, 113.7, 100.4, 38.9, 32.8.
3-(4-((2-(1H-imidazol-4-yl)ethyl)amino)quinazolin-2-yl)-4-hydroxybenzonitrile (20). Prepared according
to general procedure, 2,4-dichloroquinazoline started to afford the title compound (41 mg, 63%, pale
yellow solid); 1H NMR (400 MHz, DMSO-d6)
δ
16.00 (s, 1H), 11.87 (s, 1H), 8.97 (s, 1H), 8.81 (d, J = 2.3 Hz,
1H), 8.27 (d, J = 8.2 Hz, 1H), 7.88–7.79 (m, 1H), 7.78–7.74 (m, 2H), 7.60–7.52 (m, 2H), 7.05 (d, J = 8.6 Hz,
1H), 6.88 (s, 1H), 3.89 (d, J = 6.6 Hz, 2H), 2.98 (t, J = 7.4 Hz, 2H). 13C NMR (101 MHz, DMSO-d6)
165.3,
δ
159.5, 159.5, 146.2, 136.0, 135.3, 134.2, 134.1, 126.9, 126.3, 123.4, 120.1, 119.8, 119.3, 114.1, 100.8, 41.8, 40.6.
4-hydroxy-3-(4-(((1-methyl-1H-imidazol-4-yl)methyl)amino)quinazolin-2-yl)benzaldehyde (21). Prepared
according to general procedure, 2,4-dichloroquinazoline started to afford the title compound (12 mg,
42%, pale yellow solid); 1H NMR (400 MHz, DMSO-d6)
δ 16.06 (s, 1H), 9.94 (s, 1H), 9.26 (s, 1H), 9.02
(d, J = 2.2 Hz, 1H), 8.39 (d, J = 8.3 Hz, 1H), 7.90 (dd, J = 8.5, 2.2 Hz, 1H), 7.89–7.76 (m, 2H), 7.56 (ddd,
J = 8.1, 6.5, 1.6 Hz, 1H), 7.52 (s, 1H), 7.14 (s, 1H), 7.09 (d, J = 8.5 Hz, 1H), 4.78 (d, J = 4.9 Hz, 2H), 3.58 (s,
3H). 13C NMR (126 MHz, DMSO-d6)
δ 191.6, 167.1, 160.2, 159.3, 146.4, 134.2, 133.3, 132.9, 128.0, 126.8,
126.2, 123.7, 119.5, 118.9, 118.5, 114.1, 113.3, 99.9, 33.3.
3.5. Enzyme Inhibition Assays
The inhibitory activities of all compounds with respect to the wild type and the
d746-750/T790M/C797S mutant of EGFR were measured by Reaction Biology Corp. (Malvern, PA, USA)
using the radiometric kinase assays ([γ
-33P]-ATP). Briefly, the enzymatic reaction mixtures contained an
artificial substrate peptide, poly-Glu-Tyr (4:1) in freshly prepared base reaction buffer (20 mM HEPES
of pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.02% Brij-35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT,
1% DMSO). Wild-type and mutant EGFR were delivered into the substrate solution and gently mixed.
Each inhibitor in 100% DMSO in a serial dilution was then delivered to the reaction mixture using the
acoustic dispensing system (Echo550; nanoliter range). To initiate the enzymatic reaction, 33P-ATP
with a specific activity of 10 µCi/µL was added into the reaction mixture, and the mixture was further
incubated for 2 h at room temperature. Radioactivity was then monitored by the filter-binding method
after reactions were spotted onto P81 ion exchange paper and the filters were washed extensively in
0.75% phosphoric acid. Kinase activity data were expressed as the percent remaining kinase activity
in test samples compared to vehicle (dimethyl sulfoxide) reactions. IC50 values and curve fits were
calculated with Prism Software (GraphPad Software) at 10 different concentrations. Staurosporine was
employed as the positive control in this study.

Int. J. Mol. Sci. 2020, 21, 9323
20 of 23
3.6. Cell Proliferation Inhibition Assay
Two compounds (18 and 19) were sent to WuXi AppTec Corp., Shanghai, China, for cell proliferation
inhibition assay. The cells were treated with various concentrations of the compounds in duplicate.
After 72 h, the fluorescence signals were measured at an excitation wavelength of 540 nm and an
emission wavelength of 590 nm using a microplate reader. More specifically, the number of living cells
was determined with CellTiter-Glo® Luminescent Cell Viability Assay (Promega).
4. Conclusions
Based on the two-track virtual screening and the targeted de novo design, we discovered the
effective fourth-generation EGFR inhibitors highly selective for the d746-750/T790M/C797S mutant
over the wild type. This was made possible by virtue of the modified protein–ligand binding free
energy function involving a new hydration free energy term with enhanced accuracy. Most remarkably,
compounds 19 and 20 exhibited low-nanomolar biochemical potency against EGFRd746-750/T790M/C797S
as well as more than 104-fold selectivity over the wild type in vitro. The docking simulation results
indicated that these new inhibitors would be bound tightly in the ATP-binding pocket of the triple
mutant through the bidentate hydrogen bonds with backbone groups in the hinge region, together
with the hydrophobic interactions with the nonpolar residues in the Gly loop, hinge region, and
interdomain region. A hydrogen bond with the mutated residue Ser797 was also shown to be a
significant binding force for the fourth-generation EFGR inhibitors to be stabilized in the ATP-binding
site of the d746-750/T790M/C797S mutant. In addition to the additional interactions with the mutated
residue Met790, the establishment of a van der Waals contact with Gly loop residues and the formation
of a hydrogen bond with Asp855 in the activation loop could be invoked to account for the high
inhibitory activity and selectivity of 19 and 20, respectively. These fourth-generation EGFR inhibitors
are anticipated to serve as a lead compound for the development of new anticancer medicines against
NSCLC cells resistant to second- and third-generation EGFR inhibitor drugs.
Author Contributions: Conceptualization, H.P. and S.H.; methodology, H.P., H.-Y.J., K.K., M.K., and S.H.; software,
H.P. and S.H.; writing—original draft preparation, H.P.; writing—review and editing, H.-Y.J., K.K., and S.H.;
visualization, H.P., H.-Y.J., K.K., and S.H.; supervision, H.P. and S.H.; funding acquisition, H.P. and S.H. All
authors have read and agreed to the published version of the manuscript.
Funding: This research was supported by Basic Science Research Program through the National Research
Foundation of Korea funded by the Ministry of Education (NRF-2016R1D1A1B01014187), the KRIBB Research
Initiative Program (KGM9952011), and the Institute for Basic Science (IBS-R010-A2).
Acknowledgments: Authors wish to thank National Research Foundation of Korea (NRF-2016R1D1A1B01014187),
Korea Research Institute of Bioscience and Biotechnology (KGM9952011), and Institute for Basic Science
(IBS-R010-A2) for supporting this work.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to
publish the results.
Abbreviations
EGFR
Epidermal growth factor receptor
non-small cell lung cancer
deletion of Glu746-Ala750
pan assay interference compounds
glycine-rich loop
NSCLC
d746-750
PAINS
Gly loop
DGF
Asp855-Phe856-Gly857
protein data bank
PDB

Int. J. Mol. Sci. 2020, 21, 9323
21 of 23
References
1.
Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.;
Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non–small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139.
[CrossRef] [PubMed]
2.
3.
4.
5.
Lim, S.M.; Jeong, Y.; Hong, S. Strategies to overcome acquired resistances conferred by mutations in the
kinase domain of EGFR. Future Med. Chem. 2016, 8, 853–878. [CrossRef] [PubMed]
Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med. 2008, 359, 1367–1380. [CrossRef]
[PubMed]
Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber, D.A. Epidermal growth factor receptor mutations in lung
cancer. Nat. Rev. 2007, 7, 169–181. [CrossRef]
Kawahara, A.; Yamamoto, C.; Nakashima, K.; Azuma, K.; Hattori, S.; Kashihara, M.; Aizawa, H.; Basaki, Y.;
Kuwano, M.; Kage, M.; et al. Molecular diagnosis of activating EGFR mutations in non–small cell lung
cancer using mutation-specific antibodies for immunohistochemical analysis. Clin. Cancer Res. 2010, 16,
3163–3170. [CrossRef]
6.
7.
8.
9.
Rosell, R.; Moran, T.; Queralt, C.; Porta, R.; Cardenal, F.; Camps, C.; Majem, M.; Lopez-Vivanco, G.; Isla, D.;
Provencio, M.; et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl.
J. Med. 2009, 361, 958–967. [CrossRef]
Wang, S.; Wang, Z. EGFR mutations in patients with non-small cell lung cancer from mainland China
and their relationships with clinicopathological features: A meta-analysis. Int. J. Clin. Exp. Med. 2014, 7,
1967–1978.
Shepherd, F.A.; Pereira, J.R.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.;
Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; et al. Erlotinib in previously treated non–small-cell lung cancer.
N. Engl. J. Med. 2005, 353, 123–132. [CrossRef]
Park, J.H.; Liu, Y.; Lemmon, M.A. Radhakrishnan, Erlotinib binds both inactive and active conformations of
the EGFR tyrosine kinase domain. Biochem. J. 2012, 448, 417–423. [CrossRef]
10. Barker, A.J.; Gibson, K.H.; Grundy, W.; Godfrey, A.A.; Barlow, J.J.; Healy, M.P.; Woodburn, J.R.; Ashton, S.E.;
Curry, B.J.; Scarlett, L.; et al. Studies leading to the identification of ZD1839 (IRESSA): An orally active,
selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
Bioorg. Med. Chem. Lett. 2001, 11, 1911–1914. [CrossRef]
11. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.;
Boggon, T.J.; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.
Science 2004, 304, 1497–1500. [CrossRef]
12. Morgillo, F.; Della Corte, C.M.; Fasano, M.; Ciardiello, F. Mechanisms of resistance to EGFR-targeted drugs:
Lung cancer. ESMO Open 2016, 1, e000060. [CrossRef]
13. Eck, M.J.; Yun, C.-H. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR
mutations in non-small cell lung cancer. Biochim. Biophys. Acta 2010, 1804, 559–566. [CrossRef] [PubMed]
14. Yun, C.H.; Mengwasser, K.E.; Toms, A.V.; Woo, M.S.; Greulich, H.; Wong, K.K.; Meyerson, M.; Eck, M.J. The
T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad.
Sci. USA 2008, 105, 2070–2075. [CrossRef] [PubMed]
15. Stewart, E.L.; Tan, S.Z.; Liu, G.; Tsao, M.-S. Known and putative mechanisms of resistance to EGFR targeted
therapies in NSCLC patients with EGFR mutations–a review. Transl. Lung Cancer Res. 2015, 4, 67–81.
[PubMed]
16. Godin-Heymann, N.; Ulkus, L.; Brannigan, B.W.; McDermott, U.; Lamb, J.; Maheswaran, S.; Settleman, J.;
Haber, D.A. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an
irreversible EGFR inhibitor. Mol. Cancer Ther. 2008, 7, 874–879. [CrossRef]
17. Wang, S.; Cang, S.; Liu, D. Third-generation inhibitors targeting EGFR T790M mutation in advanced
non-small cell lung cancer. J. Hematol. Oncol. 2016, 9, 34. [CrossRef]
18. Walter, A.O.; Sjin, R.T.T.; Haringsma, H.J.; Ohashi, K.; Sun, J.; Lee, K.; Dubrovskiy, A.; Labenski, M.; Zhu, Z.;
Wang, Z.; et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated
resistance in NSCLC. Cancer Discov. 2013, 1404–1415. [CrossRef]

Int. J. Mol. Sci. 2020, 21, 9323
22 of 23
19. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.-H.; Li, D.; Capelletti, M.; Cortot, A.B.; Chirieac, L.; Iacob, R.E.;
Padera, R.; et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462,
1070–1074. [CrossRef]
20. Wang, S.; Tsui, S.T.; Liu, C.; Song, Y.; Liu, D. EGFR C797S mutation mediates resistance to third-generation
inhibitors in T790M-positive non-small cell lung cancer. J. Hematol. Oncol. 2016, 9, 59. [CrossRef]
21. Ayeni, D.; Politi, K.; Goldberg, S.B. Emerging agents and new mutations in EGFR-mutant lung cancer.
Clin. Cancer Res. 2015, 21, 3818–3820. [CrossRef] [PubMed]
22. Costa, D.B.; Kobayashi, S.S. Whacking a molecule: Clinical activity and mechanisms of resistance to third
generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl. Lung Cancer Res. 2015
4, 809–815. [PubMed]
,
23. Ercan, D.; Choi, H.G.; Yun, C.-H.; Capelletti, M.; Xie, T.; Eck, M.J.; Gray, N.S.; Jänne, P.A. EGFR mutations and
resistance to irreversible pyrimidine-based EGFR inhibitors. Clin. Cancer Res. 2015, 21, 3913–3923. [CrossRef]
24. Jia, Y.; Yun, C.-H.; Park, E.; Ercan, D.; Manuia, M.; Juarez, J.; Xu, C.; Rhee, K.; Chen, T.; Zhang, H.; et al.
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature
2016, 534, 129–132. [CrossRef]
25. Engel, J.; Becker, C.; Lategahn, J.; Keul, M.; Ketzer, J.; Muhlenberg, T.; Kollipara, L.; Schultz-Fademrecht, C.;
Zahedi, R.P.; Bauer, S.; et al. Insight into the inhibition of drug-resistant mutants of the receptor tyrosine
kinase EGFR. Angew. Chem. Int. Ed. 2016, 55, 10909–10912. [CrossRef]
26. Gunther, M.; Juchum, M.; Kelter, G.; Fiebig, H.; Laufer, S. Lung cancer: EGFR inhibitors with low nanomolar
activity against a therapy-resistant L858R/T790M/C797S mutant. Angew. Chem. Int. Ed. 2016, 55, 10890–10894.
[CrossRef] [PubMed]
27. Park, H.; Jung, H.-Y.; Mah, S.; Hong, S. Discovery of EGF receptor inhibitors that are selective for the
d746-750/T790M/C797S mutant. Angew. Chem. Int. Ed. 2017, 56, 7634–7638. [CrossRef] [PubMed]
28. Shen, J.; Zhang, T.; Zhu, S.J.; Sun, M.; Tong, L.; Lai, M.; Zhang, R.; Xu, W.; Wu, R.; Ding, J.; et al. Structure-Based
design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal
growth factor receptor triple mutant (EGFRL858R/T790M/C797S). J. Med. Chem. 2019, 62, 7302–7308. [CrossRef]
[PubMed]
29. Janne, P.A.; Von Pawel, J.; Cohen, R.B.; Crino, L.; Butts, C.A.; Olson, S.S.; Eiseman, I.A.; Chiappori, A.A.;
Yeap, B.Y.; Lenehan, P.F.; et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB
inhibitor, for previously treated advanced non–small-cell lung cancer. J. Clin. Oncol. 2007, 25, 3936–3944.
[CrossRef]
30. Ayati, A.; Moghimi, S.; Salarinejad, S.; Safavi, M.; Pouramiri, B.; Foroumadi, A. A review on progression
of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
Bioorg. Chem. 2020, 99, 103811. [CrossRef]
31. Shoichet, B.K.; Leach, A.R.; Kuntz, I.D. Ligand solvation in molecular docking. Proteins 1999, 34, 4–16.
[CrossRef]
32. Wiederstein, M.; Sippl, M.J. ProSA-web: Interactive web service for the recognition of errors in
three-dimensional structures of proteins. Nucleic Acids Res. 2007, 35, W407–W410. [CrossRef]
33. Yan, Y.; Wang, W.; Sun, Z.; Zhang, J.Z.H.; Ji, C. Protein-ligand empirical interaction components for virtual
screening. J. Chem. Inf. Model. 2017, 57, 1793–1806. [CrossRef] [PubMed]
34. Liu, Z.; Su, M.; Han, L.; Liu, J.; Yang, Q.; Li, Y.; Wang, R. Forging the basis for developing protein-ligand
interaction scoring functions. Acc. Chem. Res. 2017, 50, 302–309. [CrossRef] [PubMed]
35. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to
estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliver. Rev.
1997, 23, 3–25. [CrossRef]
36. Sterling, T.; Irwin, J.J. ZINC 15–Ligand discovery for everyone. J. Chem. Inf. Model. 2015, 55, 2324–2337.
[CrossRef]
37. Baell, J.B.; Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS)
from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 53, 2719–2740. [CrossRef]
38. Muley, L.; Baum, B.; Smolinski, M.; Freindorf, M.; Heine, A.; Klebe, G.; Hangauer, D.G. Enhancement of
hydrophobic interactions and hydrogen bond strength by cooperativity: Synthesis, modeling, and molecular
dynamics simulations of a congeneric series of thrombin Inhibitors. J. Med. Chem. 2010, 53, 2126–2135.
[CrossRef]

Int. J. Mol. Sci. 2020, 21, 9323
23 of 23
39. Peng, Y.-H.; Ueng, S.-H.; Tseng, C.-T.; Hung, M.-S.; Song, J.-S.; Wu, J.-S.; Liao, F.-Y.; Fan, Y.-S.; Wu, M.-H.;
Hsiao, W.-C.; et al. Important hydrogen bond networks in indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor
design revealed by crystal structures of imidazoleisoindole derivatives with IDO1. J. Med. Chem. 2016, 59,
282–293. [CrossRef]
40. Gajiwala, K.S.; Feng, J.; Ferre, R.; Ryan, K.; Brodsky, O.; Weinrich, S.; Kath, J.C.; Stewart, A. Insights into
the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 2013, 21, 209–219.
[CrossRef]
41. Sali, A.; Blundell, T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993
234, 779–815. [CrossRef] [PubMed]
,
42. Zhang, X.; Gureasko, J.; Shen, K.; Cole, P.A.; Kuriyan, J. An allosteric mechanism for activation of the kinase
domain of epidermal growth factor receptor. Cell 2006, 125, 1137–1149. [CrossRef] [PubMed]
43. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic generation of 3D-atomic coordinates for organic molecules.
Tetrahedron Comput. Methodol. 1990, 3, 537–547. [CrossRef]
44. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking
using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998
19, 1639–1662. [CrossRef]
,
45. Park, H.; Lee, J.; Lee, S. Critical assessment of the automated AutoDock as a new docking tool for virtual
screening. Proteins 2006, 65, 549–554. [CrossRef]
46. Park, H.; Shin, Y.; Choe, H.; Hong, S. Computational design and discovery of nanomolar inhibitors of IκB
kinase β. J. Am. Chem. Soc. 2015, 137, 337–348. [CrossRef] [PubMed]
47. Shin, S.; Mah, S.; Hong, S.; Park, H. Discovery of low micromolar dual inhibitors for wild type and L1196M
mutant of anaplastic lymphoma kinase through structure-based virtual screening. J. Chem. Inf. Model. 2016
,
56, 802–810. [CrossRef]
48. Park, H.; Shin, Y.; Kim, J.; Hong, S. Application of fragment-based de novo design to the discovery of selective
picomolar inhibitors of glycogen synthase kinase-3 beta. J. Med. Chem. 2016, 59, 9018–9034. [CrossRef]
49. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity a rapid access to atomic
charges. Tetrahedron 1980, 36, 3219–3228. [CrossRef]
50. Mehler, E.L.; Solmajer, T. Electrostatic effects in proteins: Comparison of dielectric and charge models. Protein
Eng. 1991, 4, 903–910. [CrossRef]
51. Stouten, P.F.W.; Frömmel, C.; Nakamura, H.; Sander, C. An effective solvation term based on atomic
occupancies for use in protein simulations. Mol. Simul. 1993, 10, 97–120. [CrossRef]
52. Park, H. Extended solvent-contact model approach to SAMPL4 blind prediction challenge for hydration free
energies. J. Comput. Aided Mol. Des. 2014, 28, 175–186. [CrossRef] [PubMed]
53. Chung, K.-C.; Park, H. Accuracy enhancement in the estimation of molecular hydration free energies by
implementing the intramolecular hydrogen bond effects. J. Cheminform. 2015, 7, 57. [CrossRef]
54. Wang, R.; Gao, Y.; Lai, L. LigBuilder: A multi-purpose program for structure-based drug design. J. Mol. Model.
2000, 6, 498–516. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
©
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).